Key result
Subcutaneous ICD use in 62 patients with inherited arrhythmia syndromes effectively terminated all 20 spontaneous ventricular tachyarrhythmias, with only 2 patients experiencing inappropriate shocks.
Why the study?
Does the subcutaneous implantable cardioverter-defibrillator effectively and safely treat ventricular arrhythmias in patients with inherited arrhythmia syndromes?
Population
62 consecutive patients with primary hereditary arrhythmia syndromes fulfilling indication for defibrillator…
Design
Cohort
Follow-up
mean 31.0±14.2 months
Authors
Loading...
Supports S-ICD first-shock efficacy in inherited syndromes; leaves open need for randomized trials before practice change.
Cohort (n=62)
No
Does the subcutaneous implantable cardioverter-defibrillator effectively and safely treat ventricular arrhythmias in patients with inherited arrhythmia syndromes?
The subcutaneous ICD is an effective and safe alternative to transvenous ICDs for primary and secondary prevention of sudden cardiac death in patients with inherited arrhythmia syndromes, demonstrating reliable shock efficacy and a low rate of inappropriate shocks.
Rudic et al. (2017) conducted a cohort in Inherited Arrhythmia Syndromes (n=62). Subcutaneous Implantable Defibrillator (S-ICD) was evaluated on Efficacy and safety of subcutaneous ICD (appropriate shocks, inappropriate therapies, infections). Subcutaneous ICD use in 62 patients with inherited arrhythmia syndromes effectively terminated all 20 spontaneous ventricular tachyarrhythmias, with only 2 patients experiencing inappropriate shocks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: